Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5192996
Max Phase: Preclinical
Molecular Formula: C32H53N11O7
Molecular Weight: 703.85
Associated Items:
ID: ALA5192996
Max Phase: Preclinical
Molecular Formula: C32H53N11O7
Molecular Weight: 703.85
Associated Items:
Canonical SMILES: N=C(N)N[C@@H]1CCOCNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2ccccc2)CNC(=O)CNC(=O)CNC1=O
Standard InChI: InChI=1S/C32H53N11O7/c33-13-6-4-10-23-30(48)40-20-50-15-12-25(43-32(35)36)29(47)39-19-27(45)38-18-26(44)37-17-22(16-21-8-2-1-3-9-21)28(46)41-24(31(49)42-23)11-5-7-14-34/h1-3,8-9,22-25H,4-7,10-20,33-34H2,(H,37,44)(H,38,45)(H,39,47)(H,40,48)(H,41,46)(H,42,49)(H4,35,36,43)/t22-,23-,24-,25+/m0/s1
Standard InChI Key: INHPREGOZLFYLU-OJJQZRKESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 703.85 | Molecular Weight (Monoisotopic): 703.4129 | AlogP: -3.23 | #Rotatable Bonds: 11 |
Polar Surface Area: 297.77 | Molecular Species: BASE | HBA: 10 | HBD: 11 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.69 | CX Basic pKa: 11.02 | CX LogP: -4.70 | CX LogD: -11.79 |
Aromatic Rings: 1 | Heavy Atoms: 50 | QED Weighted: 0.06 | Np Likeness Score: 0.57 |
1. Huber S, Braun NJ, Schmacke LC, Quek JP, Murra R, Bender D, Hildt E, Luo D, Heine A, Steinmetzer T.. (2022) Structure-Based Optimization and Characterization of Macrocyclic Zika Virus NS2B-NS3 Protease Inhibitors., 65 (9.0): [PMID:35475620] [10.1021/acs.jmedchem.1c01860] |
Source(1):